{"version":"1.0","type":"link","title":"A novel anticancer natural product SP09 selectively targets KRAS-mutant NSCLC through LKB1/AMPK/mTOR modulation: implications for novel therapeutic development.","author_name":"Yue P 외","author_url":"https://prs-insight.online/author/Yue%20P","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/97936","thumbnail_width":1200,"thumbnail_height":630}